Pfizer and AstraZeneca Vaccines Effective Against Variant from India, Study Finds

Coronavirus vaccines from Pfizer and AstraZeneca have been shown to work against a variant first identified in India, according to a study by Public Health England.

Two doses of the Covid-19 vaccines were “highly effective” against the B.1.617.2 strain first detected in India, the agency said in a statement. There was minimal difference with how the inoculations work on a variant detected in Kent, it said.

“We expect the vaccines to be even more effective at preventing hospitalization and death,” said Mary Ramsay, head of immunization at PHE. “So it is vital to get both doses to gain maximum protection against all existing and emerging variants.”

The results are likely to boost the U.K. government’s plan to end its lockdown on June 21 even as cases of the variant have been rising rapidly.

The study, conducted from April 5 to May 16, found that the Pfizer-BioNTech shot was 88% effective against the B.1.617.2 variant two weeks after the second dose. Two doses of the AstraZeneca vaccine were 60% effective.

The difference may be explained by the fact that the rollout of second doses of AstraZeneca came later than for the Pfizer vaccine, Public Health England said. There’s also data showing the AstraZeneca inoculation takes longer to reach maximum effectiveness, according to the agency.

Subscribe to our YouTube channel

Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.

To watch complete coverage on Bloomberg Quicktake 24/7, visit or watch on Apple TV, Roku, Samsung Smart TV, Fire TV and Android TV on the Bloomberg app.

Have a story to tell? Fill out this survey for a chance to have it featured on Bloomberg Quicktake

Connect with us on…

Breaking News on YouTube